Calendario›REGN›ALN-SNCA

ALN-SNCA

First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)

Ensayo de REGENERON PHARMACEUTICALS, INC. en Parkinsons Disease (del registro, en inglés).

Fase

Fase 1

Estado

Reclutando pacientes

Participantes

46

previstos

Centros

3

Fin del objetivo primario

jun 2029

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en dic 2025.

Qué mide

Occurrence of Treatment-Emergent Adverse Events (TEAEs) (Through Week 80) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching an experimental drug called ALN-SNCA (called "study drug"). The study is focused on people with early Parkinson's disease, a disorder of the nervous system that affects movement. Parkinson's disease is caused by a gradual loss of nerve cells in the brain, especially those due to the harmful build-up of a protein called α-synuclein. The aim of the study is to see if the study drug is safe and tolerated well enough to continue testing it in future studies and what side effects may happen from taking the study drug. The study is looking at several other research questions, including: * Whether the study drug can lower the level of α-synuclein protein in the Cerebrospinal Fluid (also referred to as "CSF", the fluid that surrounds the brain and spinal cord) * How much study drug is in the blood, urine, and CSF at different times

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07216066), actualizada en sep 2026.